Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison

Table 2 Virological responses of hepatitis C virus-infected patients receiving directly-acting antivirals therapy before and during campaign of hepatitis C virus micro-elimination in Penghu prison in Penghu prison

Undetectable HCV RNA, n/N (%)	Total	Sporadic HCV therapy in outpatient clinics (January 1, 2019 - December 31, 2019)	Campaign of HCV micro-elimination with simplified pan-genotypic SOF/VEL regimen (January 1, 2020 - March 31, 2020)	P value
Intention-to-treat population
Treatment 4 wk	284/303 (93.7)	85/91 (93.4)	199/212 (93.9)	0.879
End-of-treatment	300/303 (99.0)	91/91 (100.0)	209/212 (98.6)	0.557
End-of 12 wk follow-up	289/303 (95.4)	86/91 (94.5)	203/212 (95.8)	0.126
Per-protocol population
Treatment 4 wk	284/301 (94.4)	85/901 (94.4)	199/2112 (94.3)	0.964
End-of-treatment	300/300 (100.0)	91/91 (100.0)	209/2093 (100.0)	-
End-of 12 wk follow-up	289/290 (99.7)	86/874 (98.9)e5	203/2036 (100.0)	0.126

¹One missing data.

²One transferred; One missing data.

³Two transferred; One released.

⁴Four released.

⁵One relapser.

⁶Four transferred; Five released. HCV: Hepatitis C virus; VEL: Velpatasvir; SOF: Sofosbuvir.